| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 35.0 | 40.2 |
| Gross profit | 13.5 | 15.9 |
| Profit before tax | -21.3 | -36.0 |
| Net income | -21.6 | -33.5 |
| EPS (diluted, $ a share) | $-0.46 | $-0.73 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -13.1% |
|---|---|
| Gross margin | 38.6% |
| Operating margin | -64.3% |
10-Q filed with the SEC, NASDAQ: QTRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Quanterix Corp: key numbers
- Share price
- $2.84Close, Nov 16
- Market cap
- $135M
- Shares outstanding
- 47.48MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Quanterix Corp
All →Quanterix Financial Results
Quanterix reported Q3 2026 revenue of $35.0 million, representing a 6.3% sequential increase despite market softness. The company ended the quarter with $80.7 million in cash and marketable securities while narrowing its net loss by 35.6% year-over-year to $21.6 million. Management highlighted new commercial leadership and expanded insurance coverage for its Alzheimer’s disease blood tests as key growth drivers.
- Term
- Q3 2026
“We delivered higher than expected topline growth in the third quarter, with revenues up 6.3% sequentially, despite continued market softness. This first step in restoring growth reflects sequential improvement across all our businesses.”
Everett Cunningham, President & CEO
“We are confident about the benefits and differentiated positioning of our research tools and diagnostics businesses, especially with new commercial leadership focused on sustained growth.”
Everett Cunningham, President & CEO